Applied Therapeutics Inc

NASDAQ:APLTUnited States

May 9, 2024

Show headlines and story abstract

• -- Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000, from 7:04AM ET on Thursday May 09, 2024 by MT Newswires

  7:04AM ET on Thursday May 09, 2024 by MT Newswires
  Companies Mentioned: APLT
  07:04 AM EDT, 05/09/2024 (MT Newswires) -- ...

• Applied Therapeutics Reports First Quarter 2024 Financial Results, from 7:01AM ET on Thursday May 09, 2024 by Dow Jones

  7:01AM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: APLT
  
  Such risks and uncertainties include, without limitation, (i) our plans to develop, market and commercialize our product candidates, (ii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iii) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (iv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (v) our ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies, (vi) our ability to maintain and establish collaborations or obtain additional funding, (vii) our ability to obtain and timing of regulatory approval of our current and future product candidates, (viii) the anticipated indications for our product candidates, if approved, (ix) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (x) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, (xi) the implementation of our business model and strategic plans for our business and product candidates, (xii) our intellectual property position and the duration of our patent rights, (xiii) developments or disputes concerning our intellectual property or other proprietary rights, (xiv) our expectations regarding government and third-party payor coverage and reimbursement, (xv) our ability to compete in the markets we serve, (xvi) the impact of government laws and regulations and liabilities thereunder, (xvii) developments relating to our competitors and our industry, (xviii) our ability to achieve the anticipated benefits from the agreements entered into in connection with our partnership with Advanz Pharma and (xiv) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
  

• *DJ Applied Therapeutics 1Q Loss/Shr 67c >APLT, from 7:01AM ET on Thursday May 09, 2024 by Dow Jones

  7:01AM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: APLT

• Applied Therapeutics Reports First Quarter 2024 Financial Results, from 7:00AM ET on Thursday May 09, 2024 by GlobeNewswire

  7:00AM ET on Thursday May 09, 2024 by GlobeNewswire
  Companies Mentioned: APLT